LATTICEFLOW-AI
LatticeFlow AI, the leading Artificial Intelligence (AI) platform for enabling enterprises to build performant, safe, and trustworthy AI systems at scale, today announced the appointment of Tom Ulrich as Senior Vice President and General Manager for North America. More recently, Tom served as Vice President of Sales, Financial Services at C3.AI, where he played a key role in launching the company’s AI banking business which led to a successful IPO in 2019 (NYSE:AI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201601542/en/
(Graphic: Business Wire)
Tom’s appointment follows LatticeFlow AI’s strategic expansion into the US market. With over 25 years of experience, Tom has proven expertise in building and developing world class sales teams for high-growth enterprise SaaS companies.
“Tom brings unmatched expertise in scaling early to mid-stage tech companies into hyper-growth phases. At LatticeFlow AI, Tom will play a vital role in accelerating our growth trajectory by identifying strategic business opportunities and driving revenue growth in the North American market,” said Petar Tsankov, CEO & Co-founder of LatticeFlow AI.
Earlier in his career, Tom held various sales leadership roles at MicroStrategy, where he helped grow the company from $20 million to $500 million, culminating in a successful IPO (NASDAQ:MSTR). Throughout his professional journey, Tom has remained steadfast in his dedication to helping clients unlock business value through data-driven insights.
"As AI becomes increasingly integral in our daily lives, ensuring model trust, safety, and a positive societal impact is more important than ever. I’m excited and honored to join the LatticeFlow AI team, collaborating with some of the best AI engineers in the world who are focused on tackling these challenges. I look forward to helping our customers harness the power of AI, while accelerating model performance and safety,” said Tom Ulrich.
“Tom joining LatticeFlow AI serves as yet another testimonial to the Company’s ability to attract world-class talent,” stated Andre Boisvert, Chairman of LatticeFlow AI. “Tom’s extensive experience in building global sales teams across five distinct enterprise software companies, with a particular focus on predictive analytics and AI, underscores his invaluable potential for propelling LatticeFlow AI's advancement.”
Tom received an MBA from George Washington University with a major in International Business and is based in Vienna, VA.
About LatticeFlow AI
Founded by world renowned AI researchers from ETH Zurich, LatticeFlow AI enables enterprise companies to develop production-ready machine learning models at scale. By systematically identifying and fixing model and data issues at scale, we help enterprises unlock the true potential of AI. Additionally, we offer a comprehensive technical AI assessment to assist enterprises achieve regulatory compliance, reliability and robustness for their mission-critical AI applications. LatticeFlow AI has won several awards including the AI Privacy Challenge in April 2023, followed by the Swiss AI Award and the US Army Global AI Award.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201601542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom